Systems Immunogenetics of Influenza Virus Infection in the Collaborative Cross
Systems Immunogenetics of Influenza Virus Infection in the Collaborative Cross
批准号:
10238910
负责人:
Mark T Heise
金额:
$42.09万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-05 至 2024-08-31
关键词:
AddressAffectAllergensAntiviral AgentsAntiviral ResponseAutoimmunityAutomobile DrivingAwarenessBackBiological ModelsCandidate Disease GeneClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsData SetDiagnosisDiseaseDisease OutcomeEnvironmental Risk FactorEthicsGene CombinationsGene ExpressionGene Expression ProfilingGenesGeneticGenetic VariationHealthHumanHypersensitivityImmuneImmune Response GenesImmune System DiseasesImmune responseImmunityImmunogeneticsInbreedingIndividualInfectionInfluenza A virusLungLung diseasesMapsMediatingModelingMorbidity - disease rateMusNatural ImmunityOutcomePathogenesisPathologicPathway interactionsPatientsPhenotypePlayPopulationProcessQuantitative Trait LociRecombinantsReproducibilityResearchResearch DesignResourcesRoleSARS coronavirusSamplingShapesSignal PathwaySystemTestingTherapeutic InterventionTimeVariantVirusVirus DiseasesVirus ReplicationWest Nile virusadaptive immune responseadaptive immunitybiodefensecausal variantcohortdifferential expressionemerging pathogengene interactiongenetic testinggenetic variantgenome editinggenomic locushuman diseaseimmunological statusinfluenza infectionmortalitymouse geneticsnovelpathogenpathogenic viruspreventive interventionprogramsrespiratory virusresponsetherapeutic targettoolvaccine efficacyvaccine safety
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract: Respiratory viruses, such as influenza A virus (IAV) cause high levels of morbidity and mortality in
human populations. Host immune responses can play either protective or a pathologic role during infection.
Therefore, understanding of the regulatory networks and signaling pathways that determine the magnitude and
quality of an individual's antiviral immune response has important implications for human health, since these
genes/pathways could be therapeutically targeted to control viral replication, to treat aberrant immune
responses, or they may represent targets for enhancing the safety and efficacy of vaccines against a wide
range of viral pathogens.
Polymorphic host genes and regulatory networks have a major impact on immune response variation in human
populations. However, confounding environmental factors and/or ethical concerns limit the types of studies
that can be conducted in humans. Therefore, genetically tractable model systems that capture the range of
genetic and phenotypic diversity seen in humans are needed to mechanistically dissect the genetics of immune
variation. To address this need, we have used the Collaborative Cross (CC), a highly diverse mouse genetic
reference population, to identify and characterize polymorphic host genes that regulate baseline and IAV-
induced innate and adaptive immunity. As part of this effort, we have quantified variation in virus-induced
innate and adaptive immune responses and disease over a 45 day time-course (Days 2, 4, 7, 10, 15, 28, and
45 post infection) in a panel of 110 CC RIX lines (reproducible F1 crosses between CC recombinant inbred
(RI) lines that model heterozygous human populations). This resource, when combined with other
complementary Systems Genetics tools, such as the Diversity Outbred (DO) population and CRISPR-mediated
genome editing, data sets comparing the host response to other pathogens that are being studied in the
context of this U19, and the analysis of gene expression changes and genetic variations in IAV infected human
patients, gives us the opportunity to: 1) identify polymorphic genes associated with IAV immune response
variation, and test their impact on other aspects of the antiviral response or virus-induced disease process, 2)
test how these genes impact responses to other viral pathogens, or function during allergy/auto-immunity, and
3) test the impact of these genes in the context of human infections to identify targets for diagnosis, prevention
and therapeutic interventions in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Broad Spectrum Direct Acting Antivirals Against Emerging Alphaviruses
-
批准号:10513688
-
项目类别:
-
资助金额:$710.04万
-
财政年份:2022
-
负责人:Mark T Heise
-
依托单位:
TRIM Interactions with Arthritic Alphaviruses
-
批准号:8415508
-
项目类别:
-
资助金额:$18.19万
-
财政年份:2012
-
负责人:Mark T Heise
-
依托单位:
Pathogenesis of Chikungunya virus
-
批准号:8375894
-
项目类别:
-
资助金额:$21.32万
-
财政年份:2012
-
负责人:Mark T Heise
-
依托单位:
TRIM Interactions with Arthritic Alphaviruses
-
批准号:8249185
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2012
-
负责人:Mark T Heise
-
依托单位:
Pathogenesis of Chikungunya virus
-
批准号:8234196
-
项目类别:
-
资助金额:$20.15万
-
财政年份:2011
-
负责人:Mark T Heise
-
依托单位:
Pathogenesis of Chikungunya virus
-
批准号:7671949
-
项目类别:
-
资助金额:$11.31万
-
财政年份:2009
-
负责人:Mark T Heise
-
依托单位:
Togavirus Tropism for Bones, Joints, and CNS
-
批准号:7928648
-
项目类别:
-
资助金额:$21.55万
-
财政年份:2009
-
负责人:Mark T Heise
-
依托单位:
Improved Vaccines for Rift Valley Fever Virus
-
批准号:7473550
-
项目类别:
-
资助金额:$47.3万
-
财政年份:2008
-
负责人:Mark T Heise
-
依托单位:
Improved Vaccines for Rift Valley Fever Virus
-
批准号:7586676
-
项目类别:
-
资助金额:$47.39万
-
财政年份:2008
-
负责人:Mark T Heise
-
依托单位:
Improved Vaccines for Rift Valley Fever Virus
-
批准号:7787472
-
项目类别:
-
资助金额:$45.64万
-
财政年份:2008
-
负责人:Mark T Heise
-
依托单位:
Immune Evasion Mechanisms of Neurovirulent Alphaviruses
-
批准号:7372970
-
项目类别:
-
资助金额:$28.8万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Immune Evasion Mechanisms of Neurovirulent Alphaviruses
-
批准号:7728264
-
项目类别:
-
资助金额:$28.89万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Arbovirus Evasion of Type I Interferon Induction
-
批准号:7202170
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Arbovirus Evasion of Type I Interferon Induction
-
批准号:7380005
-
项目类别:
-
资助金额:$17.76万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Immune Evasion Mechanisms of Neurovirulent Alphaviruses
-
批准号:8196845
-
项目类别:
-
资助金额:$28.6万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Immune Evasion Mechanisms of Neurovirulent Alphaviruses
-
批准号:7994179
-
项目类别:
-
资助金额:$28.6万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Immune Evasion Mechanisms of Neurovirulent Alphaviruses
-
批准号:7531806
-
项目类别:
-
资助金额:$29.12万
-
财政年份:2007
-
负责人:Mark T Heise
-
依托单位:
Core-- Animal Models
-
批准号:6915414
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2004
-
负责人:Mark T Heise
-
依托单位:
TOGAVIRUS TROPISM FOR BONES, JOINTS, AND CNS
-
批准号:6375362
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2000
-
负责人:Mark T Heise
-
依托单位:
TOGAVIRUS TROPISM FOR BONES, JOINTS, AND CNS
-
批准号:6652043
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2000
-
负责人:Mark T Heise
-
依托单位:
海外基金